Immunotherapy Clinical Trial
Official title:
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed
HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as
first-line options for advanced HCC. The PD-1 monoclonal antibody,such as nivolumab and
pembrolizumab, have been approved to treat the patients with advanced HCC by the FDA.
Combining radiotherapy with immune checkpoints showed promising response rates and improved
survival in several solid tumor types. The purpose of this randomized study is to determine
whether stereotactic body radiation therapy (SBRT) combined with sintilimab (an anti-PD-1
antibody) will improve the response to the anticancer treatment compared to sintilimab alone
in patients with advanced HCC.
About 84 participants will be enrolled in this study. All will take part at West China
Hospital, Sichuan University.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | July 1, 2023 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Histologically confirmed hepatocellular carcinoma or diagnosed by American Association for the Study of Liver Disease criteria; 2. Deemed ineligible for curative intent therapy with surgical resection or liver transplantation. 3. Estimated life expectancy =12 weeks; 4. Male or female subjects with age: 18-70 years old 5. Failure in first-line systemic treatment with sorafenib or Lenvatinib 6. Unwilling to receive or unable to tolerate first-line treatment with sorafenib 7. Have ECOG performance status 0-1 8. Have measurable disease based on RECIST 1.1. 9. Pretreatment CT chest /abdomen /pelvis within 28 days of protocol enrollment. 10. Child-Pugh class A liver function (assessed within 14 days of SBRT); 11. The function of important organs meets the following requirements: a. white blood cell count (WBC) = 3.0×109/L, absolute neutrophil count (ANC) = 1.5×109/L; b. platelets = 50×109/L; c. hemoglobin = 8g/dL; d. serum albumin = 3.0g/dL; e. total bilirubin = 2.0×ULN, ALT, AST = 5×ULN; f. serum creatinine = 1.5×ULN 12. Must have at least one lesion amenable to SBRT. 13. Ability to understand the study and sign informed consent. Exclusion Criteria: 1. A history of abdominal radiotherapy; 2. Presence of active hepatitis B (HBV DNA = 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay); 3. Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result) 4. History of organ transplantation or allogeneic bone marrow transplantation,or other acquired or congenital immunodeficiency diseases 5. Receipt of live, attenuated vaccine within 30 days prior to the study treatment 6. Has a known history of active TB (Bacillus Tuberculosis). 7. Uncontrolled intercurrent illness including, but not limited to digestive tract ulcer, uncontrolled hypertension, fracture, uncured wound, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 8. Prior invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, lobular or ductal carcinoma in situ of the breast that has been surgically cured 9. Female patients who are pregnant or lactating 10. Untreated central nervous system (CNS) metastatic disease, lepto-meningeal disease, or cord compression 11. Active infection requiring systemic therapy 12. Presence of clinically meaningful ascites,hydrothorax or hydropericardium and patients requiring non pharmacologic intervention (eg, paracentesis) or escalation in pharmacologic intervention to maintain symptomatic control 13. Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 24-week progression-free survival (PFS) ratev | The proportion of patients with progression disease according to mRECIST at 24 weeks from randomization. | 24 weeks after radiotherapy | |
Secondary | Objective Response Rate (ORR) | Investigator assessed ORR using RECIST v1.1 including the all tumor, the tumor undergoing LDRT and the tumor which do not receive radiotherapy. | up to 24 months after the enrollment | |
Secondary | Overall Survival (OS) | OS is defined as the difference (in months) between the date of study enrollment to the date death due to any cause | up to 24 months after the enrollment | |
Secondary | 24-week disease control rate (DCR) | The proportion of patients with complete response, partial response or stable disease according to mRECIST at 24 weeks from randomization. | 24 weeks after radiotherapy | |
Secondary | Duration of response (DOR) | From date of first CR/PR to the date of first PD according to RECIST criteria, assessed up to 24 months. | up to 24 months after the enrollment | |
Secondary | Adverse Events | Treatment-related adverse events are graded according to the Common Toxicity Criteria, version 4.0, and were registered from the date of informed consent until discontinuation of trial treatment. | 2 years from randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05848011 -
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT06165900 -
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
|
Phase 2 | |
Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
Recruiting |
NCT06262581 -
Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
|
Phase 2 | |
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
Recruiting |
NCT04500990 -
MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
|
||
Not yet recruiting |
NCT04372732 -
Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
|
||
Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
Completed |
NCT03763630 -
MAPS & ITEC Cohorts: 6-8 Years Follow-up
|
Phase 2 | |
Not yet recruiting |
NCT06012318 -
Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
|
||
Not yet recruiting |
NCT05479240 -
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT04711330 -
Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
|
||
Recruiting |
NCT03683407 -
Effect of Chemotherapy on TMB in NSCLC
|
||
Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
Completed |
NCT03357861 -
Cancer Patients Treated With Immunotherapy in Intensive Care Unit
|
||
Recruiting |
NCT05223088 -
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT05657262 -
Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas
|
N/A |